Sasha Stafford on Advancing Drug Delivery Systems
Reflecting on his career, Sasha Stafford valued the immense scale at which science could improve human health. During his tenure at the Wyss Institute, he developed a drug delivery platform centered on click alginate-based hydrogels. While his professional focus has evolved, he remains optimistic that these past innovations will reach patients and revolutionize the future of medical treatment and healthcare efficacy.
What did you focus on?
I spearheaded an Institute Project that developed a drug delivery platform utilizing click alginate-based hydrogels.
Our team utilized sodium alginate that was cross-linked via click chemistry to establish a covalent network with a low mesh size. Click chemistry described certain reactions that were simple to execute, water-compatible, and produced high yields with few byproducts. By applying this method, we crosslinked the sodium alginate in a manner that permitted us to adjust the hydrogel matrix without disturbing the internal molecules like cells or proteins. The resulting hydrogel functioned like gelatin containing fruit pieces. To release the fruit—which in our research represented the drug—we had to manipulate specific bonds to ensure the therapeutic load remained intact during delivery. This versatile system was designed to potentially transport small molecules, biologics, or nano-particles. I am eager to see how current researchers continue to refine these systems for the next generation of precision medicine.
What challenges did this work address?
For decades, drug delivery methods held immense potential that remained largely unmet. Our research focused on bypassing the failures of previous techniques. We delivered therapeutics directly to target sites, which reduced required dosages while preventing systemic toxicity. This localized approach increased treatment efficacy significantly. I am hopeful that the field of drug delivery will soon fulfill the promise it has held for so many years. During my time there, we targeted difficult areas like the brain and eyes. After demonstrating safety in those sensitive regions, we shifted focus toward different, less complex applications. Looking forward, I expect to see these methodologies adopted across various medical disciplines to enhance patient outcomes globally.
What was your specific role?
I served as a Staff Scientist and was a key member of the Advanced Technology Team (ATT). In that capacity, I moved the click alginate project toward commercialization and acted as a repository of knowledge for numerous projects within the Immuno-Materials Platform. Over my ten-year tenure, I witnessed the full lifecycle of various research initiatives. The Wyss was a unique environment where a project might last from several months to a few years. If a concept was not yet ready for the market, it was often redirected for further engineering. I took pride in being a guide for other researchers, sharing precisely what had succeeded or failed in earlier iterations to ensure their efforts built upon established knowledge. Today, I maintain a deep interest in seeing how those foundational insights catalyze future breakthroughs in biotechnology and engineering.
While at the Wyss, I was privileged to not only create inventions but also guide the translation of truly novel technologies.
— Sasha Stafford
Functioning within the Advanced Technology Team required a deep understanding of industry standards, which we applied daily. We utilized regulatory frameworks such as GMPs and GLPs to validate our work. A major part of my job involved de-risking technologies using industry-grade experience to ensure they transitioned from academic publications to actual patient care. I understood the rigorous requirements needed for Phase 1 clinical trials, so I planned our development timeline by working backward from that goal. This industry-first perspective provided a distinct advantage for the Wyss in the race toward translation. I continue to advocate for this clinical-readiness approach as the most effective path for the future of biomedical innovation and patient accessibility.
How did you and the ATT bridge the gap between academic research and commercial industry requirements during your time at the Wyss?
What drives your outlook today?
I am motivated by the prospect of seeing medical breakthroughs reach the bedside to alleviate patient suffering. Most people face health trials eventually. I believe the future of drug delivery will provide the solutions they deserve.